SeekingAlpha · Jul 24, 2026
ImmuCell: First Defense With Better Execution
ImmuCell's main value driver is First Defense. This is their core franchise and has real commercial momentum across year-round dairy customers. See why ICCC stock is a Buy.
IC
NASDAQ · ICCC
ImmuCell Corporation
Healthcare · Biotechnology
$9.76
Up+$0.06 (+0.62%)
Updated Aug 19, 2026, 9:23 AM
SID Score
5.1/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 54.28M
- P/E ratio
- 23.36
- Dividend yield
- 0.00%
- 52-week range
- $6.00 – $12.10
- Volume
- 15.15K
- Avg. volume
- 18.99K
Price performance
ICCC price history
1M range · 21 trading sessions · Daily adjusted prices
ICCC closed at $9.76 after 21 trading sessions, down 12.82% for the selected period.
- Last close
- $9.76
- Period change
- -12.82%
- Period low
- $9.70
- Period high
- $11.24
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 18, 2026 | $9.73 | $9.86 | $9.6291 | $9.76 | 15.15K |
| Aug 17, 2026 | $10.00 | $10.00 | $9.55 | $9.70 | 100.99K |
| Aug 14, 2026 | $10.72 | $10.72 | $9.75 | $10.05 | 92.03K |
| Aug 13, 2026 | $10.96 | $11.1399 | $10.86 | $10.90 | 44.7K |
| Aug 12, 2026 | $10.80 | $11.06 | $10.47 | $10.98 | 26.83K |
| Aug 11, 2026 | $11.06 | $11.09 | $10.62 | $10.95 | 14.49K |
| Aug 10, 2026 | $11.098 | $11.098 | $10.865 | $10.97 | 12.15K |
| Aug 7, 2026 | $10.95 | $11.03 | $10.7582 | $11.00 | 9.71K |
| Aug 6, 2026 | $10.82 | $11.31 | $10.62 | $11.02 | 41.57K |
| Aug 5, 2026 | $11.16 | $11.3788 | $10.5001 | $10.75 | 15.13K |
| Aug 4, 2026 | $10.99 | $11.25 | $10.91 | $11.07 | 27.58K |
| Aug 3, 2026 | $11.33 | $11.33 | $10.99 | $11.04 | 16.44K |
| Jul 31, 2026 | $10.98 | $11.35 | $10.97 | $11.21 | 10.15K |
| Jul 30, 2026 | $11.01 | $11.22 | $10.82 | $11.06 | 24.9K |
| Jul 29, 2026 | $11.20 | $11.20 | $10.90 | $11.01 | 25.25K |
| Jul 28, 2026 | $11.25 | $11.35 | $11.175 | $11.24 | 8.69K |
| Jul 27, 2026 | $11.10 | $11.24 | $11.04 | $11.13 | 15.24K |
| Jul 24, 2026 | $10.91 | $11.165 | $10.91 | $11.03 | 8.71K |
| Jul 23, 2026 | $11.00 | $11.16 | $10.90 | $10.93 | 19.74K |
| Jul 22, 2026 | $11.12 | $11.67 | $10.9501 | $11.13 | 23.54K |
| Jul 21, 2026 | $11.08 | $11.64 | $11.04 | $11.195 | 16.15K |
Latest ICCC news
The latest Smart Investors Daily articles mentioning ICCC.
Stock researchCompany · Overview
ICCC research
Overview
Company profile and research snapshot.
Company profile
ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 13, 2020 | Aegis Capital | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Jul 9, 2026
ImmuCell Q2 Total Product Sales Rises 12%
ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), an animal health biologics company that develops, manufactures and markets products to improve calf health and productivity,
Finnhub · Apr 13, 2026
ImmuCell Bolsters its Innovation Strategy with Appointments of Dr. Gilles Guillemette and Dr. Anthony DiMarco to the Board, and Moves to a Smaller Board of Independent Directors
PORTLAND, Maine, April 13, 2026 -- ImmuCell Corporation , an animal health biologics company that develops and markets products to improve calf health and productivity, announced that Dr. Gilles...
Benzinga · Apr 9, 2026
ImmuCell shares are trading higher after the company reported year-over-year increase in its Q1 preliminary sales results.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
